Abiraterone for newly diagnosed high-risk hormone-sensitive metastatic prostate cancer: final appraisal document

In this DRAFT guidance abiraterone with prednisone/prednisolone plus androgen deprivation therapy (ADT) is not recommended, as trials may overestimate effectiveness and cost-effectiveness estimates vs. ADT alone and docetaxel plus ADT.

National Institute for Health and Care Excellence